UR9.MU Clinuvel Pharmaceuticals Limited
- Market cap
- EUR 815M
- P/E
- 11.4x
- P/B
- 1.84x
- ROE
- 12.4%
- Dividend yield
- 0.11%
- Fundamental score
- 2.7/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is UR9.MU undervalued?
Graham numberUR9.MU trades 3.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Clinuvel Pharmaceuticals Limited fundamental analysis
14 of 22 checks passedROE 1/2
Moderate return on equity (12.4%), between 10% and 20%.
ROA 1/1
Return on assets (11.5%) is above the industry median (3.2%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-6.8%) is not above the 5-year average (6.1% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-6.8%) is below the industry median (6.0%).
Revenue Growth 1/2
Revenue grew 6.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 1/1
PE (11.4x) is below the market median (16.6x).
PE vs Industry 1/1
PE (11.4x) is below the industry median (16.6x).
PBV 0/1
Price to book (1.8x) is above the industry median (1.8x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 20.9, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 1.86, above 1.
Dividend Yield 0/2
Dividend yield (0.7%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 8 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 7.4%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Clinuvel Pharmaceuticals Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Clinuvel Pharmaceuticals Limited
There is no Profile data available for UR9.MU.
Full company profileClinuvel Pharmaceuticals Limited financial statements
Clinuvel Pharmaceuticals Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 16.7M | 25.5M | 31.0M | 32.6M | 48.0M | 65.7M | 78.3M | 88.2M | 95.0M | 94.0M |
| Gross Profit | 12.7M | 19.5M | 24.2M | 22.9M | 43.3M | 55.2M | 69.5M | 78.1M | 79.1M | 78.2M |
| Operating Income | 6.75M | 12.2M | 16.7M | 11.8M | 28.2M | 35.3M | 44.1M | 48.0M | 45.7M | 39.5M |
| EBITDA | - | - | 18.1M | 13.2M | 28.2M | 37.4M | 49.6M | 56.3M | 57.2M | 40.5M |
| Net Income | 7.18M | 13.2M | 18.1M | 16.6M | 24.7M | 20.9M | 30.6M | 35.6M | 36.2M | 33.9M |
| EPS | 0.15 | 0.28 | 0.37 | 0.34 | 0.50 | 0.42 | 0.62 | 0.71 | 0.72 | 0.67 |
| Balance Sheet | ||||||||||
| Total Assets | 28.6M | 42.9M | 62.3M | 81.5M | 109M | 144M | 194M | 231M | 272M | 295M |
| Total Liabilities | 3.16M | 3.49M | 5.17M | 7.87M | 9.83M | 18.4M | 29.1M | 28.1M | 30.9M | 22.2M |
| Shareholders' Equity | 25.4M | 39.4M | 57.2M | 73.7M | 98.7M | 126M | 165M | 203M | 241M | 273M |
| Cash & Short-term Investments | 23.8M | 36.2M | 54.3M | 66.7M | 82.7M | 122M | 157M | 184M | 224M | 252M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 9.92M | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | 67.5K | 75.1K | 258K | 889K | 854K | 434K | 1.03M | 5.58M | 299K | 1.60M |
| Free Cash Flow | 9.85M | 11.6M | 18.2M | 13.3M | 18.4M | 39.4M | 35.9M | 31.5M | 40.8M | 35.3M |
| Ratios | ||||||||||
| ROE | 28.3% | 33.6% | 31.7% | 22.6% | 25.0% | 16.6% | 18.6% | 17.6% | 15.0% | 12.4% |
| ROA | 25.1% | 30.8% | 29.1% | 20.4% | 22.8% | 14.5% | 15.8% | 15.4% | 13.3% | 11.5% |
| Net Profit Margin | 42.9% | 51.9% | 58.4% | 51.1% | 51.5% | 31.8% | 39.1% | 40.4% | 38.1% | 36.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Clinuvel Pharmaceuticals Limited dividends
- Dividend yield
- 0.11%
- Forward dividend
- 0.02 EUR
- Payout ratio
- 7.4%
- Ex-dividend date
- Sep 3, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | AUD 2.51M | 0.05 | 7.4% |
| 2025 | AUD 2.50M | 0.05 | 6.9% |
| 2024 | AUD 2.47M | 0.05 | 6.9% |
| 2023 | AUD 1.98M | 0.04 | 6.5% |
| 2022 | AUD 1.24M | 0.03 | 5.9% |
| 2021 | AUD 1.24M | 0.03 | 5.0% |
| 2020 | AUD 1.22M | 0.02 | 7.4% |
| 2019 | AUD 957K | 0.02 | 5.3% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Nov 12, 2010.
Who owns Clinuvel Pharmaceuticals Limited
- Insiders 23.87%
- Institutions 11.94%
- Public & others 64.20%
- Shares outstanding 47.8M
Clinuvel Pharmaceuticals Limited company profile
- Company name
- Clinuvel Pharmaceuticals Limited
- Ticker
- UR9.MU
- Exchange
- Munich Exchange
- Sector
- Other
- Industry
- Metals & Mining
- Fiscal year end
- June
- Address
- 535 Bourke Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9660 4900
- Website
- clinuvel.com
About Clinuvel Pharmaceuticals Limited
There is no Profile data available for UR9.MU.
Clinuvel Pharmaceuticals Limited management
4- Dr. Philippe Jacques WolgenMD, CEO & Director · born 1963
- Mr. Darren M. KeamyCFO & Company Sec. · born 1973
- Dr. Dennis J. Wright BPharm, M.Sc., Ph.D.Acting Chief Scientific Officer
- Lachlan HayGen. Mang. of Europe